Significant progress made in new COVID-19 vaccine developed by the team of Prof Salanti On Tuesday January 12 th, in Nature Communications, strong preclinical results for a new COVID-19 vaccine, developed by the team of Prof. Salanti from University of Copenhagen, ExpreS 2ion Biotech, its joint venture partner AdaptVac and the PREVENT-nCoV consortium, was published. Based on these results, a clinical trial application (CTA) for a clinical Phase I/II study for the COVID-19 vaccine has been submitted. About the preclinical results Readouts from the data show that ABNCoV2 has the potential to be the best-in-class COVID-19 vaccine with a more than 100-fold higher level of neutralizing antibodies compared with published preclinical animal data from currently approved COVID-19 vaccines, such as Pfizer-BioNTech's, Moderna's, and AstraZeneca-Oxford's vaccines. The full paper is available online and can be read here.